Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD urged to overturn decision on flunixin
Flunixin is a common analgesic used in horses with colic

Product suspended over potential risk to humans

Leading equine veterinary association BEVA is urging the Veterinary Medicines Directorate (VMD) to overturn its decision to suspend the sale of flunixin.

Flunixin is a common analgesic used in horses with colic, as well as for those undergoing surgery and other conditions. On Thursday (26 July), the VMD suspended the product after the Committee for Medicinal Products for Veterinary Use (CVMP) said that a solvent in the injectable formulation - diethanolamine - could pose a risk to humans.

Now BEVA is calling on the VMD to overturn this decision in horses not destined for the human food chain, to reduce the potential impact on equine welfare. It argues that the decision had been made without warning or consultation with the veterinary profession.

“BEVA is fully supportive of all attempts to promote food safety, however, flunixin is widely viewed as the gold-standard painkiller in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic,” said BEVA president Jonathan Pycock.

“BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue.

“BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”

Used widely throughout the veterinary industry, flunixin is the only medicine licensed for the treatment of sepsis. BEVA states that no recall notices have been issued and therefore veterinary surgeons may continue to prescribe medicines that are in stock.

A disruption to the supply chain, however, could lead to shortages of this medicine in clinical practic, it said. 

Image (C) Redwings Horse Sanctuary

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.